Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Tumor ablation · Arizona | Tumor ablation · California | |
|---|---|---|
| Surgeons, 2024 | 3 | 8 |
| Medicare fee-for-service cases | 264 | 940 |
| Growth since 2019 (Medicare FFS) | +12%/yr | −1.6%/yr |
| Forecast cases (Medicare FFS) | 460 in 2030 | 1,020 in 2030 |
| Forecast growth | +9.6%/yr to 2030 | +1.4%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 0.4 | 0.3 |
| Medicare Advantage share | 54% | 56% |
| Out of hospital | 0% (+0 pts since 2019) | 0% (+0 pts since 2019) |
| Cases per surgeon | 88 | 118 |
| Top 10 surgeons' share | 100% | 100% |
| Surgeons growing | 0 | 0 |
| New since the base year | 0 | 1 |
| Likely to stop billing it | 2 by 2026 | 5 by 2026 |
| Forecast miss, 1 year (procedure) | 15% | 15% |
| Company payments per surgeon | $89K | $132K |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.